LANTUS VS STANDARD CARE VS PLACEBO IN IFG, IGT AND EARLY TYPE II DIABETES MELLIT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 Origin研究将评估有大血管事件高风险的IGT、IFG和早期2型糖尿病患者是否可以安全地将甘精胰岛素治疗到接近正常的血糖水平。据推测，与将根据正常指南进行跟踪和治疗的对照组相比，这种治疗将降低他们未来发生大血管和微血管事件的风险。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ORIGIN Study will evaluate whether people with IGT, IFG, and early type 2 diabetes who are at high risk for macrovascular events can be safely treated wih insulin glargine to near normal levels of blood glucose. It is hypothesized that this treatment will reduce their risk for future macrovascular and microvascular events compared to a control group who will be followed and treated according to normal guidelines.